Roth Affirms BioBlast Pharma (ORPN) at 'Buy' Following Q1 Report; U.S. Phase II/III HOPEMD Enrollment Remains Next Milestone
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $18 price target on BioBlast Pharma Ltd. (Nasdaq: ORPN) following hte company's Q1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
